- Home
- FC vs KZIA Comparison
FC vs KZIA Comparison
Compare FC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FC | KZIA |
|---|---|---|
| Founded | 1983 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.2M | 161.5M |
| IPO Year | 1992 | 1999 |
Fundamental Metrics
Financial Performance| Metric | FC | KZIA |
|---|---|---|
| Price | $16.14 | $9.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $24.50 | $17.67 |
| AVG Volume (30 Days) | 151.5K | ★ 2.0M |
| Earning Date | 01-07-2026 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $267,067,000.00 | $1,199,108.00 |
| Revenue This Year | $3.17 | N/A |
| Revenue Next Year | $4.00 | N/A |
| P/E Ratio | $70.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.04 | $2.86 |
| 52 Week High | $39.22 | $21.00 |
Technical Indicators
Market Signals| Indicator | FC | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 46.60 |
| Support Level | $15.68 | $11.75 |
| Resistance Level | $17.02 | $17.40 |
| Average True Range (ATR) | 0.62 | 2.77 |
| MACD | 0.19 | -0.22 |
| Stochastic Oscillator | 63.60 | 20.00 |
Price Performance
Historical ComparisonAbout FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.